MSFT   212.64 (-0.78%)
FB   242.16 (-0.96%)
AMZN   3,188.69 (+0.19%)
NVDA   420.51 (+0.04%)
BABA   258.79 (-1.07%)
GE   6.67 (+1.37%)
TSLA   1,414.76 (+1.47%)
T   29.78 (+0.78%)
F   5.97 (+2.05%)
DIS   118.78 (+1.68%)
BAC   23.27 (+2.20%)
BA   175.33 (+1.18%)
MSFT   212.64 (-0.78%)
FB   242.16 (-0.96%)
AMZN   3,188.69 (+0.19%)
NVDA   420.51 (+0.04%)
BABA   258.79 (-1.07%)
GE   6.67 (+1.37%)
TSLA   1,414.76 (+1.47%)
T   29.78 (+0.78%)
F   5.97 (+2.05%)
DIS   118.78 (+1.68%)
BAC   23.27 (+2.20%)
BA   175.33 (+1.18%)
MSFT   212.64 (-0.78%)
FB   242.16 (-0.96%)
AMZN   3,188.69 (+0.19%)
NVDA   420.51 (+0.04%)
BABA   258.79 (-1.07%)
GE   6.67 (+1.37%)
TSLA   1,414.76 (+1.47%)
T   29.78 (+0.78%)
F   5.97 (+2.05%)
DIS   118.78 (+1.68%)
BAC   23.27 (+2.20%)
BA   175.33 (+1.18%)
MSFT   212.64 (-0.78%)
FB   242.16 (-0.96%)
AMZN   3,188.69 (+0.19%)
NVDA   420.51 (+0.04%)
BABA   258.79 (-1.07%)
GE   6.67 (+1.37%)
TSLA   1,414.76 (+1.47%)
T   29.78 (+0.78%)
F   5.97 (+2.05%)
DIS   118.78 (+1.68%)
BAC   23.27 (+2.20%)
BA   175.33 (+1.18%)
Log in

NASDAQ:PTCTPTC Therapeutics Stock Price, Forecast & News

$55.93
-0.95 (-1.67 %)
(As of 07/10/2020 11:12 AM ET)
Add
Compare
Today's Range
$55.51
Now: $55.93
$56.71
50-Day Range
$47.78
MA: $51.08
$57.07
52-Week Range
$30.79
Now: $55.93
$59.89
Volume3,375 shs
Average Volume684,574 shs
Market Capitalization$3.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.4
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Read More
PTC Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$306.98 million
Book Value$9.64 per share

Profitability

Net Income$-251,580,000.00

Miscellaneous

Employees511
Market Cap$3.66 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

How has PTC Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTCT stock has increased by 18.8% and is now trading at $55.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PTC Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PTC Therapeutics.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for PTC Therapeutics.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.00) by $0.81. The biopharmaceutical company had revenue of $68.30 million for the quarter, compared to analysts' expectations of $81.90 million. PTC Therapeutics had a negative return on equity of 46.42% and a negative net margin of 90.83%. PTC Therapeutics's revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.29) EPS. View PTC Therapeutics' earnings history.

What price target have analysts set for PTCT?

8 analysts have issued 12-month price targets for PTC Therapeutics' stock. Their forecasts range from $45.00 to $85.00. On average, they expect PTC Therapeutics' share price to reach $62.83 in the next twelve months. This suggests a possible upside of 12.3% from the stock's current price. View analysts' price targets for PTC Therapeutics.

Has PTC Therapeutics been receiving favorable news coverage?

Media coverage about PTCT stock has trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PTC Therapeutics earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about PTC Therapeutics.

Who are some of PTC Therapeutics' key competitors?

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), Regulus Therapeutics (RGLS), NVIDIA (NVDA), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD).

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the following people:
  • Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 59)
  • Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 73)
  • Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 41)
  • Mr. Marcio Souza, Chief Operating Officer (Age 40)
  • Dr. Neil Almstead, Chief Technical Operations Officer (Age 52)

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.01%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View institutional ownership trends for PTC Therapeutics.

Which institutional investors are buying PTC Therapeutics stock?

PTCT stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View insider buying and selling activity for PTC Therapeutics.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $55.93.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $3.66 billion and generates $306.98 million in revenue each year. The biopharmaceutical company earns $-251,580,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is www.ptcbio.com.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.